LEO Pharma - International Clinical Trial Manager

Vitrolife wants to acquire Medicult

The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.

Norwegian cancer therapy leaves phase II

New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.

Parnevik firm in Swiss osteoporosis deal

The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.

View pathology images in your iPhone

The Institute for Medical Informatics in Oslo announces a brand new iPhone application for virtual microscopy.

Biogaia's advance goes on

In December Biogaia reached China and North America. Now, the Swedish probiotic company has entered the Mexican market.

Danish discovery could help cardiac patients

The Danish researchers have developed a component that could make live easier forpatients with heart failure.

New Nordic nutrition collaboration

Scandinavian Clinical Nutrition has recently signed a unique Nordic distribution agreement.

Bio engineering breakthrough in Denmark

Brand new research makes BioGasol's cellulosic ethanol process even more competitive.

Swedish cancer therapy granted

Pledpharma, Linköping University and Ryhov County Hospital receive a research grant from the Research Council FORSS to conduct clinical studies in cancer patients.

Sales Representative, Applied Biosystems

Meda gets access to Asia

The biotech giant Meda has recently acquires world-wide rights to the cancer breakthrough pain drug Onsolis.

Academy for a new turn at work

Are you qualified within life science, but unemployed? Here is your chance for a new career, in high demand.

Bring talent to those in need

Ho ho ho, Christmas time is here again. So get busy decking the halls, perhaps not with assorted greenery, but with something of a more lasting value.

Time to save for survival

The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.

Martin Bergö: "The Idea is the Thing"

Martin Bergö, 38, goes wherever ideas take him - it's a process that has led to, and resulted from, plenty of unexpected results. Those ideas have been recognized as good ones: in 2008, he was awarded the Eric K. Fernström Foundation's Prize for young researchers. It isn't the first award for the Associate Professor at Gothenburg University's Sahlgrenska Academy. In 2007, he received a grant award of 16 million SEK from the European Research Council for his pioneering work.